Podium to Practice: EHA 2026 – Lymphoma: CD22 CAR-T in NHL
OR
Studies / Trials Discussed
S230 – CD22-DIRECTED CAR T-CELLS INDUCE HIGH RATES OF COMPLETE REMISSIONS WITH MINIMAL NEUROTOXICITY IN HIGH-RISK FOLLICULAR LYMPHOMA, MANTLE CELL LYMPHOMA, AND OTHER NON-HODGKIN LYMPHOMA SUBTYPES.
Co-Chairs
Speakers
Explore more from your favourite experts – click their name to access their entire library of content.
This program has been made possible through unrestricted support from Merck.
Studies/trials discussed:
S230 – CD22-DIRECTED CAR T-CELLS INDUCE HIGH RATES OF COMPLETE REMISSIONS WITH MINIMAL NEUROTOXICITY IN HIGH-RISK FOLLICULAR LYMPHOMA, MANTLE CELL LYMPHOMA, AND OTHER NON-HODGKIN LYMPHOMA SUBTYPES.
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.